Literature DB >> 8384962

Management of small-cell lung cancer.

B E Johnson1.   

Abstract

SCLC typically presents as a central endobronchial lesion in chronic cigarette smokers with hilar enlargement and disseminated disease. The diagnostic pathology should be reviewed by a pathologist who is accomplished in reading pulmonary pathology and if any doubt exists in the diagnosis, additional special stains and/or diagnostic material should be obtained. Patients with extensive stage disease should be managed by combination chemotherapy, whereas patients with limited stage disease should be treated with combination chemotherapy and chest radiotherapy. The chemotherapy should be administered for 4 to 6 months and discontinued; patients should be retreated with chemotherapy if they relapse. Prophylactic cranial radiation is an appropriate option for patients who achieve a complete remission. The patients who are in complete remission should be carefully observed for second cancers and appropriate therapy should be administered if the cancers appear.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384962

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  3 in total

1.  Carcinoembryonic antigen, tissue polypeptide antigen and neuron-specific enolase pleural levels used to classify small-cell and non-small-cell lung cancer patients by discriminant analysis.

Authors:  G Paone; G De Angelis; S Greco; F Fiorucci; A Bisetti; F Ameglio
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.

Authors:  J Walewski; J Romejko-Jarosińska; J Zwoliński; S Falkowski; P Siedlecki
Journal:  Med Oncol       Date:  1996-12       Impact factor: 3.064

3.  The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033.

Authors:  M J Naughton; J E Herndon; S A Shumaker; A A Miller; A B Kornblith; D Chao; J Holland
Journal:  Qual Life Res       Date:  2002-05       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.